Russian Federation: Greater Convergence: IP And Competition Law

Russia is a large market for pharmaceuticals, and has a population of more than 140 million, developed retail chains and a large state procurement system. Since the market is big and competition tough, effective patent protection provides invaluable tools for safeguarding the market position.

Moreover, the knowledge of key trends in the Russian legal landscape in terms of pharma patent litigation, intellectual property and regulatory issues, and approaches in interpreting the correlation between the IP aspects of competition regulations, may help to better understand the market situation from the legal prospective.


Effective on June 1, 2016, important procedural amendments (obligatory complaint procedures) will come into force in terms of strategy that will affect pharma patent litigation. Currently patentees are not obliged to send cease-and-desist letters to potential defendants (manufacturers, distributors, importers of patent-infringing generic drugs).

Despite that, filing cease-and-desist letters without prior notice may have its advantages (eg, a surprise effect or a reason for the defendant to estimate the risks and stop infringing activities). Such letters may be recommended to ensure the framework for stating the bad-faith intention of the potential defendants or to seek an out-of-court settlement.

Starting from June 1, future pharma litigation lawsuits will be accompanied by evidence of the prior cease-and-desist letters sent to the defendants. A 30-day term shall pass from the date of sending the cease-and-desist letter to the defendants; otherwise the filed lawsuit will be returned to the plaintiff (which does not exclude re-filing the infringement case when the obligatory complaint procedure is complied with).

On January 1, 2016, new data exclusivity protection rules came into force in Russia. In particular, while it is still not allowed to use for commercial purposes the information on results of the pre-clinical and clinical trials—which is submitted by the originator for obtaining the marketing authorisation (MA) without the originator's consent for six years from the state registration of the original medicine in Russia—the provisions on filing the generic medicine application have changed.

That said, in comparison with the previous six years during which state registration of the generic medicine with use of the originator's data on pre-clinical and clinical trials was not allowed, after January 2016 the following changed:

An MA application for a generic medicine may be filed with the Russian Ministry of Health four years from the date of the state registration of an original medicine in Russia; and

An MA application for a biosimilar medicine may be filed with the Russian Ministry of Health three years from the date of the state registration of the original medicine in Russia.

In this regard, companies undertaking monitoring and compliance activities in Russia should adjust their internal policies (notification letters to the Russian Ministry of Health) to the extent reflecting the new legislative changes.

Russian law provides a five-year maximum for extending a pharma patent based on one MA. However, the wording of the legislation was unclear to the extent to which two or more patents may be extended based on one MA.

While considering the recent extension of nullity cases the Russian Intellectual Property Court correctly and in full compliance with the law established that the legislation does not prohibit extension of more than one patent based on one MA. The position of the IP Court in this regard may be used as an effective argument in patent extension nullity cases.

IP contests

Traditionally, IP-related agreements are exempt from the competition regulations, since IP is itself a legitimate monopoly.

Meanwhile, under Russian law parties may enter into agreements that at the same time may encompass the licensing provisions, sale and purchase aspects, as well the provisions potentially falling within competition control issues.

Russian competition legislation has detailed provisions on banning abuse of the market dominant positions; one of the forms of such abuse is a refusal by the dominant company to enter into a contract (eg, a supply agreement) when such a refusal is not economically or technologically explained.

However, the law provides that the requirements on banning abuse of market dominance do not apply to "activities on exercising the exclusive rights to IP results or means of individualisation". That provision may be characterised as an "IP defence" in cases of the dominant position abuse.

Recently, Russian judicial practice has faced issues relating to the implementation of the "IP defence" in cases where a medicine manufacturer refused to enter into a supply agreement with a distributor.

In 2010 the manufacturer and the distributor entered into a framework agreement under which the manufacturer, through separate agreements, would supply the patented and branded medicine (in its original package), while the distributor would re-package the medicine in the secondary package and start commercialising the medicine in Russia.

Later, the distributor sent a draft supply agreement to the manufacturer, who refused to enter into it. As it follows from the subsequent case file, the refusal was motivated by compliance reasons. The distributor filed a complaint with the Federal Antimonopoly Service (FAS) citing abuse of the dominant position. Upon investigation FAS established that the company holding the dominant position refused to enter into a supply agreement. The manufacturer appealed against the FAS decision to the Moscow City Commercial Court.

The court revoked the FAS decision, establishing that the refusal by the manufacturer to enter into a medicine supply agreement rested within the realm of the trademark owner's rights. Further, the court noted that the distributor had outstanding debts to the manufacturer.

FAS and the distributor appealed against the court decision to the Ninth Commercial Appellate Court, citing that FAS did not analyse the manufacturer's activities of using the exclusive rights, but the activities aimed at avoiding conclusion of the supply agreement. Furthermore, the appealing parties disagreed that the distributor had debts while the issue of debts incurred by the other companies in the distributor's group of entities was not relevant for the case.

In its opposition, the manufacturer cited that when an agreement had been entered into, trademarks rights would have been triggered. Further, the manufacturer submitted that the medicine at issue was protected with patents owned by the manufacturer.

The appellate court revoked the first instance decision and upheld the FAS decision. The reasoning of the appellate court was that as competition law states that refusal to enter into an agreement shall be motivated technologically, economically or otherwise, which would exclude the chance to enter into the supply agreement as had been defined in the framework agreement between the distributor and manufacturer.

In its decision, the appellate court agreed with FAS that the manufacturer's motives (the distributor's necessity to undergo compliance under the US Federal Corruption Practices Act; the intention of the manufacturer to commercialise the medicine via its subsidiary; and the debts incurred by the companies affiliated with the distributor) could not be recognised in this specific case as falling within "economical and technological motives".

While analysing the "IP defence" implementation in that particular case, the appellate court noted that the essence of the right to commercialise the medicine is the exclusive right of the patentee to make a decision on commercialisation of the medicine in Russia.

However, as the appellate court noted, the patentee shall take account of the competition law restrictions, which the court found to have been breached in the present case.

Meanwhile, the court also cited the "exhaustion of rights" defence—according to which commercialisation of a specific number of patent-protected products is not an infringement of exclusive rights if the same number of products has been previously supplied to Russia by the patentee or with its consent.

Further, regarding the invocation of "trademark rights", the court noted that the subject matter of the specific agreement in this case was in fact "supply of goods".

The appellate court decision was upheld by the Commercial Court of the Moscow region and the Russian Federation Supreme Court.

The implications of the case generally fall into line with the trends of the Russian competition regulator paying more attention to correlation between IP rights and the competition restrictions, which will require solid legal expertise for distribution chains.

The Russian IP legal landscape in which life sciences companies operate requires constant monitoring of legislative developments and trends in judicial practice to achieve knowledge-based tools in the current market situation.

Originally published by Life Sciences Intellectual Property Review.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions